When it comes to HRT, according to professional societies, there is a lack of safety data supporting the use of systemic (oral or transdermal) HRT in women who have had breast or ovarian cancer. The risk of breast cancer recurrence with HRT is higher in those with estrogen receptor positive cancer, but patients with estrogen receptor negative breast cancer may also have an increased risk of the cancer regrowing.
